Literature DB >> 20838378

The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.

R Piñeiro1, T Maffucci, M Falasca.   

Abstract

Recently, the orphan receptor G protein-coupled receptor 55 (GPR55) has been proposed as a potential cannabinoid receptor, although controversy remains on its physiological roles. Current evidence suggests a role for GPR55 as a receptor for the lysophospholipid lysophosphatidylinositol (LPI). In this study, we show that GPR55 is expressed in several prostate and ovarian cancer cell lines, both at the mRNA and at the protein level, and that it has a critical role in regulating proliferation and anchorage-independent growth. We further show that GPR55 mediates the effects of LPI in prostate and ovarian cancer cells. Indeed we demonstrate that LPI is able to induce calcium mobilization and activation of Akt and extracellular signal-regulated kinase (ERK)1/2 in these cells and that both pharmacological blockade of GPR55 and its downregulation using specific small interfering RNA strongly inhibits these processes. We further identify an autocrine loop by which LPI is synthesized by cytosolic phospholipase A2, pumped out of the cell by the ATP-binding cassette transporter ABCC1/MRP1, and is then able to initialize cascades downstream of GPR55. All together, these data demonstrate a role of LPI and its receptor GPR55 in cancer cells in activating an autocrine loop that regulates cell proliferation. These findings may have important implications for LPI as a novel cancer biomarker and for its receptor GPR55 as a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20838378     DOI: 10.1038/onc.2010.417

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  83 in total

1.  Lysophosphatidylinositol stimulates [³⁵S]GTPγS binding in the rat prefrontal cortex and hippocampus.

Authors:  Maria Luisa Rojo; Antonio Rodriguez-Gaztelumendi; Christopher J Fowler
Journal:  Neurochem Res       Date:  2012-01-22       Impact factor: 3.996

2.  Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones.

Authors:  Maria Elena Meza-Aviña; Mary A Lingerfelt; Linda M Console-Bram; Thomas F Gamage; Haleli Sharir; Kristen E Gettys; Dow P Hurst; Evangelia Kotsikorou; Derek M Shore; Marc G Caron; Narasinga Rao; Larry S Barak; Mary E Abood; Patricia H Reggio; Mitchell P Croatt
Journal:  Bioorg Med Chem Lett       Date:  2016-02-16       Impact factor: 2.823

3.  The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling.

Authors:  Xiao-Lei Zhou; Xin Guo; Yu-Pin Song; Chong-Yue Zhu; Wei Zou
Journal:  Acta Pharmacol Sin       Date:  2017-11-30       Impact factor: 6.150

4.  Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands.

Authors:  Evangelia Kotsikorou; Karla E Madrigal; Dow P Hurst; Haleli Sharir; Diane L Lynch; Susanne Heynen-Genel; Loribelle B Milan; Thomas D Y Chung; Herbert H Seltzman; Yushi Bai; Marc G Caron; Larry Barak; Mary E Abood; Patricia H Reggio
Journal:  Biochemistry       Date:  2011-06-01       Impact factor: 3.162

5.  Concurrent activation of β2-adrenergic receptor and blockage of GPR55 disrupts pro-oncogenic signaling in glioma cells.

Authors:  Artur Wnorowski; Justyna Such; Rajib K Paul; Robert P Wersto; Fred E Indig; Krzysztof Jozwiak; Michel Bernier; Irving W Wainer
Journal:  Cell Signal       Date:  2017-05-08       Impact factor: 4.315

6.  Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling.

Authors:  N A Balenga; E Martínez-Pinilla; J Kargl; R Schröder; M Peinhaupt; W Platzer; Z Bálint; M Zamarbide; I G Dopeso-Reyes; A Ricobaraza; J M Pérez-Ortiz; E Kostenis; M Waldhoer; A Heinemann; R Franco
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

7.  GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.

Authors:  R Ferro; A Adamska; R Lattanzio; I Mavrommati; C E Edling; S A Arifin; C A Fyffe; G Sala; L Sacchetto; G Chiorino; V De Laurenzi; M Piantelli; O J Sansom; T Maffucci; M Falasca
Journal:  Oncogene       Date:  2018-07-30       Impact factor: 9.867

8.  (R,R')-4'-methoxy-1-naphthylfenoterol targets GPR55-mediated ligand internalization and impairs cancer cell motility.

Authors:  Rajib K Paul; Artur Wnorowski; Isabel Gonzalez-Mariscal; Surendra K Nayak; Karolina Pajak; Ruin Moaddel; Fred E Indig; Michel Bernier; Irving W Wainer
Journal:  Biochem Pharmacol       Date:  2013-12-16       Impact factor: 5.858

9.  THC Reduces Ki67-Immunoreactive Cells Derived from Human Primary Glioblastoma in a GPR55-Dependent Manner.

Authors:  Marc Richard Kolbe; Tim Hohmann; Urszula Hohmann; Chalid Ghadban; Ken Mackie; Christin Zöller; Julian Prell; Jörg Illert; Christian Strauss; Faramarz Dehghani
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.639

10.  Glycerophosphodiesterase 3 (GDE3) is a lysophosphatidylinositol-specific ectophospholipase C acting as an endocannabinoid signaling switch.

Authors:  Fabienne Briand-Mésange; Véronique Pons; Sophie Allart; Julien Masquelier; Gaëtan Chicanne; Nicolas Beton; Bernard Payrastre; Giulio G Muccioli; Jérôme Ausseil; Jean-Luc Davignon; Jean-Pierre Salles; Hugues Chap
Journal:  J Biol Chem       Date:  2020-09-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.